8-KEarnings & ResultsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Financial Results (Jan 31, 2018)

Filed January 31, 2018For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K report on January 31, 2018, announcing its financial results for the fourth quarter and full year ended December 31, 2017. The primary purpose of this filing is to incorporate by reference the press release detailing these results, which was issued concurrently. Investors should refer to the press release (Exhibit 99.1) for the comprehensive financial performance data, including revenue, earnings, and any forward-looking statements or guidance provided by the company.

Key Highlights

  • 1Vertex Pharmaceuticals reported its consolidated financial results for the three and twelve months ended December 31, 2017.
  • 2The announcement was made via a press release issued on January 31, 2018.
  • 3The press release detailing the financial results is attached as Exhibit 99.1 to the 8-K filing.
  • 4This filing primarily serves to formally include the press release in the company's SEC filings.
  • 5Investors are directed to the press release for specific financial performance details and operational updates.
  • 6The information presented in the press release is furnished and not deemed 'filed' for certain liability purposes under the Securities Exchange Act of 1934.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally incorporate by reference Vertex Pharmaceuticals' press release, which contains their financial results for the fourth quarter and full year ended December 31, 2017. This ensures the results are part of their official SEC filings.

The detailed financial results are presented in the press release that was issued on January 31, 2018. This press release is attached as Exhibit 99.1 to the 8-K filing.

No, the information set forth in the press release (Exhibit 99.1) is furnished and shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section. It also won't be automatically incorporated into other registration statements unless specifically referenced.

The reported financial results cover the three and twelve months ended December 31, 2017.